Tirzepatide, known by brand names including Mounjaro, works differently from semaglutide. It acts on two hormone pathways rather than one, GLP-1 and GIP, both of which are involved in appetite signaling and blood sugar regulation. For some patients that dual action is a better fit. For others it is not the right choice at all. There is no ranking of these medications that applies to everyone, and anyone telling you otherwise is selling rather than practicing.
What we do first is look. Lab work, medical history, current prescriptions, and any family history of thyroid or pancreatic conditions all factor into whether tirzepatide is appropriate. If it is, dosing starts low and increases on a schedule your physician sets, with check-ins along the way. Digestive side effects are the most common thing patients experience, and we would rather you hear about that in the exam room than discover it on a Tuesday night.
We are a single office at 5009 Roswell Road NE in Buckhead, not a chain, and we have been doing this work since 2010. Patients making the trip from the southside usually take I-85 north to GA-400 or come around on I-285. If you are coming from near the Gateway Center Arena or the Main Street district, the mid-morning and early-afternoon appointment slots tend to be the least painful on that stretch of highway.
About Tirzepatide Weight Loss
Tirzepatide is a once-weekly injectable medication that acts on two gut hormone receptors at the same time, GIP and GLP-1. Both hormones are released naturally after a meal, and both influence how full you feel, how quickly the stomach empties, and how the body handles insulin and blood sugar. Because tirzepatide engages both pathways rather than one, many patients find that persistent hunger quiets down and that smaller portions feel satisfying. It is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes; the active molecule is the same in both.
The FDA approved tirzepatide for type 2 diabetes in 2022, for chronic weight management in late 2023, and for moderate-to-severe obstructive sleep apnea in adults with obesity at the end of 2024. In the 72-week SURMOUNT-1 trial, adults without diabetes lost an average of about 16 percent of body weight on the 5 mg dose and about 21 to 22 percent on the 10 and 15 mg doses, compared with roughly 2 percent on placebo. A later head-to-head trial, SURMOUNT-5, reported an average reduction near 20 percent with tirzepatide versus about 14 percent with semaglutide over the same period. These are averages across large study populations, not a forecast for any one person. Individual response varies a great deal, and some patients respond only modestly.
At Atlanta Medical Institute, tirzepatide is prescribed inside a supervised medical weight loss program rather than as a standalone prescription. A physician reviews your health history, current medications, and lab work before deciding whether the medication is appropriate, and eligibility is determined by that medical evaluation. Treatment is paired with nutrition guidance, protein and resistance-training recommendations to help protect lean mass, and scheduled follow-up so the dose can be adjusted to what your body actually tolerates.
What treatment actually involves
Tirzepatide is given as a small subcutaneous injection once a week, on the same day each week, into the abdomen, thigh, or back of the upper arm. Most patients give the injection themselves after being shown how at the office. The needle is short and fine, and the injection is usually described as a brief pinch rather than a painful procedure.
Dosing starts low and increases slowly. The standard approach begins at 2.5 mg weekly for four weeks, which is a starting dose intended to let the digestive system adjust rather than a treatment dose. From there the dose may be raised in 2.5 mg steps no more often than every four weeks, with common maintenance doses of 5 mg, 10 mg, or 15 mg once weekly. Your physician decides how quickly to move and where to stop, and many patients do well without ever reaching the maximum dose. If side effects appear, holding at a dose longer or stepping back down is a normal part of the process, not a failure.
- Once-weekly subcutaneous injection, self-administered at home
- Typical start: 2.5 mg weekly for four weeks before any increase
- Dose increases of 2.5 mg no more often than every four weeks
- Common maintenance doses: 5 mg, 10 mg, or 15 mg weekly
- Store pens refrigerated; a limited period at room temperature is permitted per the product labeling
- Missed dose guidance depends on timing, so ask before doubling up
Who is a candidate
For chronic weight management, the FDA-approved population is adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, abnormal cholesterol, or obstructive sleep apnea. The medication is approved for use alongside a reduced-calorie diet and increased physical activity, not in place of them. Patients with type 2 diabetes may be candidates for tirzepatide under its diabetes indication instead, which is a separate clinical decision.
Some patients should not take tirzepatide at all. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, in anyone with multiple endocrine neoplasia syndrome type 2, and in anyone with a serious hypersensitivity reaction to the drug. It carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether that risk translates to humans has not been established, but the contraindication is firm. It is not recommended in pregnancy and is generally stopped in advance of a planned pregnancy.
Other histories call for caution rather than an automatic no: prior pancreatitis, gallbladder disease, severe gastroparesis or other significant gastrointestinal disease, diabetic retinopathy, kidney disease, and a history of an eating disorder. Patients taking insulin or a sulfonylurea may need those medications reduced to lower the risk of hypoglycemia. Patients using oral hormonal contraceptives are advised by the label to add a barrier method or switch to a non-oral option for four weeks after starting and after each dose increase, because delayed stomach emptying can affect absorption. This is exactly the kind of detail a physician evaluation is meant to catch.
What to expect over the first year
The first month is usually about tolerance, not results. At 2.5 mg, appetite changes are often noticeable but weight change may be small. Most of the meaningful movement happens as the dose steps up over the following months, and trial data show weight continuing to decline well past the six-month mark before flattening. Patients who see very little response after several months at an adequate dose should have that conversation with their physician rather than simply waiting longer; sometimes a different medication or a different approach is the better answer.
Eating patterns change. Portions that were normal before may feel like too much, carbonation and greasy or very rich foods often become less appealing, and it becomes easy to under-eat protein without noticing. Body composition analysis from SURMOUNT-1 found that roughly three quarters of the weight lost was fat mass and about one quarter was lean mass, a ratio broadly in line with what happens during substantial weight loss generally. Deliberate protein intake and resistance training are the practical tools for protecting muscle, and they are discussed as part of treatment rather than left to chance.
Tirzepatide is a treatment for a chronic condition, not a course of therapy with a finish line. Studies in which the medication is withdrawn show that a significant portion of lost weight tends to return. Some patients stay on a maintenance dose long term, some step down to a lower dose, and some transition off with a structured plan. That decision belongs to you and your physician, and it is worth discussing early so that the long-term picture is clear before treatment starts.
Safety, side effects, and monitoring
The most common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, abdominal discomfort, burping, and reduced appetite. They are typically mild to moderate, cluster in the first few months and around dose increases, and often settle with time, smaller meals, adequate fluids, and a slower titration schedule. Injection site reactions, fatigue, and hair shedding during rapid weight loss are also reported.
Less common but more serious concerns include pancreatitis, gallbladder problems including gallstones and inflammation, kidney injury from dehydration during prolonged vomiting or diarrhea, and severe or persistent gastrointestinal symptoms that warrant stopping the medication. Severe abdominal pain, especially pain radiating to the back and accompanied by vomiting, should be treated as urgent and evaluated the same day. Because tirzepatide slows stomach emptying, you should tell any surgeon, proceduralist, or anesthesiologist that you are taking it well before a scheduled procedure requiring sedation.
Supervision is the point of treating with this medication in a physician's office. Expect a baseline evaluation that typically includes weight and vital signs, a review of every medication and supplement you take, a personal and family history focused on thyroid and pancreatic disease, and blood work appropriate to your situation, which often covers A1c, a metabolic panel, and lipids. Follow-up visits are scheduled around the titration schedule so that side effects, dose changes, blood pressure, glucose, and lean-mass concerns are addressed while they are still small problems.
- Common: nausea, diarrhea, constipation, vomiting, abdominal pain, reduced appetite
- Seek prompt care for: severe abdominal pain, persistent vomiting, signs of dehydration, or an allergic reaction
- Disclose tirzepatide use before any surgery or procedure involving sedation
- Insulin or sulfonylurea doses may need adjustment to avoid low blood sugar
- Ask about oral contraceptive absorption when starting and at each dose increase
- Report new neck mass, trouble swallowing, shortness of breath, or persistent hoarseness
Getting Here from College Park
Patients from College Park generally pick up I-85 north through the city to GA-400, or swing around on I-285, then exit toward Roswell Road for the Buckhead and Chastain Park stretch where the office sits.
5009 Roswell Road NE, Suite 201
Atlanta, GA 30342
We see patients from across College Park and nearby areas including Historic College Park, Main Street commercial district, Godby Road area, Camp Creek / Gateway Center area, Hapeville (adjacent).
Tirzepatide Weight Loss in College Park — Frequently Asked Questions
Should I choose tirzepatide or semaglutide?
That is a clinical decision, not a preference. The two medications work on different hormone pathways, and factors like your medical history, other conditions, current medications, and how you tolerate treatment all matter. Your physician will recommend one, both at different times, or neither.
Are there people who should not take tirzepatide?
Yes. Certain personal or family medical histories make this medication inappropriate, and some existing conditions or prescriptions rule it out. This is exactly what the evaluation and lab work are for. We do not prescribe it without that step.
Is this available to patients who live outside Atlanta proper?
Yes. We serve patients from across the metro area, including many from the College Park area, at our one office on Roswell Road in Buckhead. Call (404) 341-4819 to ask about scheduling around your commute.
How is tirzepatide different from semaglutide?
Semaglutide, sold as Wegovy and Ozempic, acts on the GLP-1 receptor. Tirzepatide acts on both the GLP-1 and the GIP receptors. In the SURMOUNT-5 head-to-head trial, average weight reduction over 72 weeks was roughly 20 percent with tirzepatide compared with about 14 percent with semaglutide. That said, group averages do not decide individual cases. Tolerability, medical history, prior response, and insurance coverage all factor in, and some patients simply do better on one than the other. Your physician will help you weigh which is the better starting point for you.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded versions are not FDA-approved products and are not reviewed by the FDA for safety, effectiveness, or manufacturing quality. During the 2023 to 2024 shortage the FDA allowed broader compounding of tirzepatide; it declared that shortage resolved in December 2024 and ended enforcement discretion for compounded tirzepatide in early 2025, and has since moved to further restrict compounding of these drugs from bulk ingredients. If any clinic offers you a GLP-1 medication, ask directly whether it is the FDA-approved product or a compounded preparation, and ask what that means for your safety and your dosing.
How much weight will I lose on tirzepatide?
No physician can tell you that in advance, and you should be skeptical of anyone who does. Published trials report average reductions of roughly 16 to 22 percent of body weight over about 72 weeks depending on dose, but individual results ranged from substantial loss to very little. Response depends on the dose you tolerate, your starting health, other medications, sleep, and how nutrition and activity change alongside the medication. What your physician can do is set a realistic expectation for your situation and adjust the plan based on what actually happens.
Do I have to stay on tirzepatide forever?
Obesity is treated as a chronic condition, and the evidence shows that when tirzepatide is stopped, a meaningful share of the lost weight tends to return for most people. Some patients remain on a maintenance dose long term, some reduce to a lower dose, and some work with their physician on a structured plan to come off it while holding the habits and nutrition changes in place. There is no single right answer, and it is a reasonable thing to discuss at your first visit rather than a year in.
Will insurance cover it?
Coverage varies widely by plan and by indication. Some commercial plans cover tirzepatide for weight management, some cover it only for type 2 diabetes or obstructive sleep apnea, and some exclude weight loss medications entirely. Plans that do cover it often require prior authorization with documentation of BMI, weight-related conditions, and previous attempts at weight management. Manufacturer savings programs exist for eligible patients with commercial coverage. Our staff can tell you what your plan requires and what the self-pay options look like before you commit to anything.
What happens at the first appointment?
It is a medical evaluation, not a sales visit. A physician reviews your weight history, medical history, family history, and every medication and supplement you take, then examines you and orders lab work as appropriate. You will talk through what has and has not worked before, what your goals are, and whether tirzepatide, a different medication, or a non-medication approach fits best. If tirzepatide is appropriate, you will leave understanding the starting dose, the titration plan, what side effects to expect, and when you will be seen again.
Want the full clinical detail? Read about our Tirzepatide Program program.